Zijie Yang; Jiachun Chen; Lan Wei; Delei Dai; Hu Tang; Yan Zhang; Wei Xie; Shaochu Liu; Wei Tan; Xiangdong Shi; Chenli Zheng; Xiaohong Yuan; Zhongliang Xu; Wei Ye; Jin Zhao; Zijie Yang; Jiachun Chen; Lan Wei; Delei Dai; Hu Tang; Yan Zhang; Wei Xie; Shaochu Liu; Wei Tan; Xiangdong Shi; Chenli Zheng; Xiaohong Yuan; Zhongliang Xu; Wei Ye; Jin Zhao

doi:10.46234/ccdcw2025.044

[1]

Han MJ. Analysis of the situation of the AIDS epidemic in China and prospects for prevention and treatment. Chin J AIDS STD 2023;29(3):247-50. http://dx.doi.org/10.13419/j.cnki.aids.2023.03.01. (In Chinese).

[2]

Zhu Y, Huang YM, Zheng CL, Tang J, Zeng G, Xie W, et al. Primary resistance to integrase inhibitors in Shenzhen. J Antimicrob Chemother 2023;78(2):546 − 9. https://doi.org/10.1093/jac/dkac442.

[3]

Zhao J, Cai R, Chen L, Cai WD, Yang ZR, Richardus JH, et al. A comparison between respondent-driven sampling and time-location sampling among men who have sex with men in Shenzhen, China. Arch Sex Behav 2015;44(7):2055 − 65. https://doi.org/10.1007/s10508-014-0350-y.

[4]

Guo JH, Kang WT, Liu TT, Xu J, Tang HL, Lyu F, et al. Analysis of knowledge level and use of antiretroviral pre-exposure and post-exposure prophylaxis among MSM - China, 2019-2022. China CDC Wkly 2023;5(13):292 − 6. https://doi.org/10.46234/ccdcw2023.053.

[5]

Yan XY, Jia ZW, Zhang B. Evaluating the risk compensation of HIV/AIDS prevention measures. Lancet Infect Dis 2022;22(4):447 − 8. https://doi.org/10.1016/S1473-3099(22)00151-7.

[6]

Zhang J, Xu JJ, Wang HY, Huang XJ, Chen YK, Wang H, et al. Preference for daily versus on-demand pre-exposure prophylaxis for HIV and correlates among men who have sex with men: the China Real-world Oral PrEP Demonstration study. J Int AIDS Soc 2021;24(2):e25667. https://doi.org/10.1002/jia2.25667.

[7]

van den Elshout MAM, Wijstma ES, Boyd A, Jongen VW, Coyer L, Anderson PL, et al. Sexual behaviour and incidence of sexually transmitted infections among men who have sex with men (MSM) using daily and event-driven pre-exposure prophylaxis (PrEP): four-year follow-up of the Amsterdam PrEP (AMPrEP) demonstration project cohort. PLoS Med 2024;21(5):e1004328. https://doi.org/10.1371/journal.pmed.1004328.

[8]

Peng QL, Liu XN, Tang X, Zhang QY, Zhao J, Zheng CL, et al. Low rate of pre-exposure prophylaxis and post-exposure prophylaxis uptake and high prevalence of transmitted drug resistance among newly diagnosed primary HIV infections in Shenzhen, China: a real-world retrospective study. Chin Med J (Engl) 2022;135(22):2730 − 7. https://doi.org/10.1097/CM9.0000000000002510.

[9]

Johnson KA, Chen MJ, Kohn R, Sachdev D, Bacon O, Lee S, et al. Acute HIV at the time of initiation of pre-exposure or post-exposure prophylaxis: Impact on drug resistance and clinical outcomes. J Acquir Immune Defic Syndr 2021;87(2):818 − 25. https://doi.org/10.1097/QAI.0000000000002638.

[10]

Elliott T, Sanders EJ, Doherty M, Ndung'u T, Cohen M, Patel P, et al. Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. J Int AIDS Soc 2019;22(12):e25419. https://doi.org/10.1002/jia2.25419.